Accelerate Diagnostics Company Overview
About Accelerate Diagnostics
Accelerate Diagnostics (NASDAQ:AXDX) specializes in developing innovative solutions aimed at combating antibiotic resistance and enhancing patient care. With a focus on rapid diagnostics, their primary project is an advanced system designed to quickly identify pathogens and ascertain their antibiotic susceptibility. This technology allows healthcare providers to make informed treatment decisions faster, potentially saving lives and reducing the spread of infections. Accelerate Diagnostics is deeply committed to advancing microbiology and improving outcomes for patients facing serious infections. By streamlining the diagnostic process, their objective is to significantly reduce the time it takes to diagnose and treat infectious diseases, thus enhancing hospital efficiency and patient care globally.
Snapshot
Operations
Products and/or services of Accelerate Diagnostics
- Rapid identification and antibiotic susceptibility testing system, shortening diagnosis time for serious infections.
- Pheno system, leveraging automation for faster detection of microbial growth.
- PhenoTest BC kit, speeding up bloodstream infection analysis.
- Software solutions for data management and analytics in clinical microbiology labs.
- Customizable assay development for hospital labs, focusing on specific pathogen detection needs.
- Research and development in new technologies for infectious disease diagnostics.
Accelerate Diagnostics executive team
- Mr. Jack PhillipsCEO, President & Director
- Mr. David PatienceChief Financial Officer
- Mr. Lawrence Michael MertzChief Technology Officer
- Ms. Maya GowriSenior VP & Head of Operations
- Ms. Laura PiersonInvestor Relations Officer
- Mr. John MeduriChief Strategy Officer
- Mr. Chris ThodeSenior Vice President of US Commercial